Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HBV mutations associated with lamivudine therapy.

Przeglad epidemiologiczny - 1 Jan 2013

Lapiński Tadeusz Wojciech, Parfieniuk-Kowerda Anna, Trzos Anna, Jaroszewicz Jerzy, Kowalczuk Oksana, Nikliński Jacek, Flisiak Robert

Abstract excerpt

UNLABELLED: Lamivudine (LMV) is still the most commonly used nucleoside analogue in majority of the world. Its administration rapidly leads to resistance associated with mutations in HBV polymerase. THE AIM of the study was to assess the prevalence, nature and the time of LMV resistant variants appearence during a long term therapy. PATIENTS AND METHODS: Study was carried out among 175 chronic hepatitis B...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis B Surface Antigens
Share to Lamivudine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross Reactions

Share to DNA-Directed DNA Polymerase

Share to Gene Products, pol

Share to Guanine

Share to Hepatitis B Antibodies

Share to Hepatitis B e Antigens

Source

Identifiers

PMID: 24741905

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HBV mutations associated with lamivudine therapy.PMID 24741905Read ↗

A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine.Semantic proximity Read ↗

Potential and limitations of lamivudine monotherapy in chronic hepatitis B: evidence from genotyping.Semantic proximity Read ↗

Character of HBV (hepatitis B virus) polymerase gene rtM204V/I and rtL180M mutation in patients with lamivudine resistance.Semantic proximity Read ↗

Prevalence and clinical characterization of patients with acute hepatitis B induced by lamivudine-resistant strains.Semantic proximity Read ↗

[Mutations of HBV polymerase gene sequence in lamivudine-resistant chronic hepatitis B patients].Semantic proximity Read ↗

[Clinical and virologic characteristics of lamivudine resistance in HBV-associated chronic liver disease].Semantic proximity Read ↗

Molecular epidemical characteristics of Lamivudine resistance mutations of HBV in southern China.Semantic proximity Read ↗

Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.Semantic proximity Read ↗

Comparative evaluation of long-term monotherapies & combination therapies in patients with chronic hepatitis B: A pilot study.Semantic proximity Read ↗

Hepatitis B virus genotypes and resistance mutations in patients under long term lamivudine therapy: characterization of genotype G in Brazil.Semantic proximity Read ↗

Pretreatment with pegylated interferon prevents emergence of lamivudine mutants in lamivudine-naive patients: a pilot study.Semantic proximity Read ↗

Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.